HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report) saw a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 1,646 shares, an increase of 269.1% from the July 30th total of 446 shares. Based on an average trading volume of 2,461 shares, the short-interest ratio is currently 0.7 days.
Wall Street Analysts Forecast Growth
Separately, Raymond James Financial upgraded HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, According to MarketBeat, the company currently has an average rating of “Strong Buy”.
Check Out Our Latest Stock Report on HLS Therapeutics
HLS Therapeutics Price Performance
HLS Therapeutics Company Profile
HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.
The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America.
Featured Stories
- Five stocks we like better than HLS Therapeutics
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
